The success of Sildenafil initially fueled a period of growth for pharma, however recent shifts present a uncertain picture for investors. Generic alternatives are eroding revenue, and persistent legal battles add https://neilibor326651.bcbloggers.com/39988594/the-blue-pill-and-pharma-a-precarious-bet